![]() | |
Clinical data | |
---|---|
Other names | CVL-871; PF-06669571; PW-0464 |
Routes of administration | By mouth |
Drug class | Dopamine receptor agonist |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H17F2N3O4 |
Molar mass | 389.359 g·mol−1 |
3D model (JSmol) | |
| |
|
Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. [1] [2] [3] [4] It is taken orally. [1]
Razpipadon acts as a selective partial agonist of the dopamine D1 and D5 receptors. [1] [2] [5] The drug has been found to increase willingness to exert effort for rewards in humans and hence appears to show pro-motivational effects. [6] [7]
The drug was originated by Pfizer and is under development by Cerevel Therapeutics. [1] As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy. [1]
Similarly, augmenting DA using a D1 agonist (PF-06412562; 6mg, 15mg, 30mg) increased willingness to exert physical effort for reward (Soutschek et al., 2020).